16
Treatment
Table 4. Medication Formulations
Brand Name Generic Name Treatment of
Strengths /
Formulations
Sublocade Buprenorphine
extended-release
Moderate to severe
OUD in patients
who have initiated
treatment with
transmucosal
buprenorphine
followed by dose
adjustment for a
minimum of 7 days
Subcutaneous injection:
100mg, 300mg
Brixadi Moderate to severe
OUD in patients
who have initiated
treatment with a single
dose of transmucosal
buprenorphine or
who are already
being treated with
buprenorphine
Subcutaneous injection:
Weekly:
8mg, 16mg, 24mg, 32mg
Monthly:
64mg, 96mg, 128mg
Probuphine Buprenorphine
hydrochloride
Treatment of OUD
in patients who
have achieved and
sustained prolonged
clinical stability on
low-to-moderate doses
of a transmucosal
buprenorphine
Implants: 80mg/implant
Revia Oral
naltrexone
a
Prevention of relapse
to OUD following
complete opioid
withdrawal
Oral tablet: 50mg
Vivitrol Extended-
release
naltrexone
Intramuscular injection:
380mg
a
Oral naltexone is NOT recommended except under very limited circumstances
(see Naltrexone section)
(cont'd)
